TrialBMC cancer2025

Randomized, phase II trial to evaluate the efficacy and safety of atezolizumab plus capecitabine adjuvant therapy compared to capecitabine monotherapy for triple receptor-negative breast cancer with residual invasive cancer after neoadjuvant chemotherapy (MIRINAE trial, KCSG-BR18-21).

Jieun Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.